XML 35 R16.htm IDEA: XBRL DOCUMENT

Shareholders' Equity

6 Months Ended

Jun. 30, 2019

Stockholders' Equity Note [Abstract]

SHAREHOLDERS' EQUITY

NOTE 9: - SHAREHOLDERS' EQUITY

Share-based compensation:

a.

On October 30, 2016, the Board resolved to increase the number of Ordinary Shares reserved under the 2013 Share Option Plan from 1,250,000 to 2,450,000.

The total number of Ordinary Shares available for future grants under the 2013 Share Option Plan as of June 30, 2019 was 712,225.

b.

The following is a summary of the Company's stock options activity for the six month period ended June 30, 2019:

		Number of options				Weighted-average exercise price				Weighted- average remaining contractual term (in years)				Aggregate intrinsic value

Outstanding at January 1, 2019			415,510			$	14.62				2.69			$	3
Granted			-				-
Exercised			(1,500	)			6.00
Expired and forfeited			(17,400	)			15.99

Outstanding at June 30, 2019			396,610			$	14.59				2.20			$	2

Vested and expected to vest at June 30, 2019			396,610			$	14.59				2.20			$	2

Exercisable at June 30, 2019			230,884			$	12.92				1.78			$	2

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the fair value of the Company's Ordinary Shares on the last day of the six month period ended June 30, 2019 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on June 30, 2019. This amount is impacted by the changes in the fair market value of the Company's Ordinary Shares.

c.

As of June 30, 2019, stock options under the 2013 Share Option Plan, as amended are as follows:

		Options outstanding at June 30, 2019												Options exercisable at June 30, 2019
Exercise price		Number outstanding				Weighted average exercise price				Weighted average remaining contractual life				Number exercisable				Weighted average exercise price				Weighted average remaining contractual life
$						$				In years								$				In years

6.00			750				6.00				0.06				750				6.00				0.06
11.12-14.52			251,708				11.87				1.72				195,133				11.88				1.63
18.90-19.85			144,152				19.39				3.05				35,001				18.90				2.64

			396,610												230,884

d.

The following is a summary of the Company's restricted stock unit ("RSU") activity for the six month period ended June 30, 2019:

		Number of RSUs				Weighted average remaining contractual term (in years)				Aggregate intrinsic value

Outstanding at January 1, 2019			168,869				1.40			$	1,253
Granted			263,220
Vested			(36,244	)
Cancelled and forfeited			(10,800	)

Outstanding at June 30, 2019			385,045				1.81			$	3,169

Vested and expected to vest at June 30, 2019			385,045				1.81			$	3,169

e.

The weighted average fair values of RSUs granted during the six month periods ended June 30, 2019 and 2018 were $7.70 and $19.62 per share, respectively.

f.

The following table summarizes the departmental allocation of the Company's share-based compensation charges:

		Six months ended June 30,
		2019*				2018*
		Unaudited

Cost of revenues		$	95			$	77
Research and development, net			357				411
Sales and marketing			330				462
General and administrative			183				392

		$	965			$	1,342

(*)

Including $772 and $827 of compensation cost related to RSUs for the six month periods ended June 30, 2019 and 2018, respectively.

g.

Share-based compensation:

As of June 30, 2019, there are $2,749 of total unrecognized costs related to non-vested share-based compensation and RSUs that are expected to be recognized over a weighted average period of 1.13 years.